Bristol-Myers Squibb Company (BMY)
|Net Income (ttm)||8.29B|
|Ex-Dividend Date||Oct 5, 2023|
|Day's Range||48.81 - 49.35|
|52-Week Range||48.42 - 81.44|
|Price Target||64.65 (+32.44%)|
|Earnings Date||Oct 26, 2023|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and p... [Read more]
In 2022, BMY's revenue was $46.16 billion, a decrease of -0.49% compared to the previous year's $46.39 billion. Earnings were $6.33 billion, a decrease of -9.54%.Financial Statements
According to 18 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is $64.65, which is an increase of 32.44% from the latest price.
Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.
Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments
Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potent...
Three-Stock Lunch: Boeing, Bristol Myers and Krispy Kreme
Sylvia Jablonski, Defiance ETFs CEO and CIO, joins 'Power Lunch' ' to discuss three stocks: Boeing, Bristol Myers and Krispy Kreme Inc.
U.S. equities began the Thanksgiving holiday-shortened trading week higher at midday after optimism about slowing inflation buoyed markets last week. The Dow, S&P 500, and Nasdaq all gained.
Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for...
Abecma, developed with 2seventy Bio, won't be approved for earlier treatments of a certain kind of blood cancer by a Dec. 16 deadline.
Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential appro...
The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio's marketing application of their blood cancer therapy, Abecma, for earlier lines of treatm...
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #2seventy--BMS and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel).
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea...
Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Augtyro--U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment.
The U.S. Food and Drug Administration (FDA) on Wednesday approved Bristol-Myers' drug to treat patients with a type of lung cancer.
With risk omnipresent in the market and more reason than 1 to fear a recession, value, yield, and beta are more critical for successful investing than ever. If nothing else, volatility should be expec...
Bristol Myers Squibb (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference.
Since early July, Bristol-Myers Squibb Co.'s (BMY, Financial) share price has been under downward pressure due, in part, to growing concerns among financial market participants about the ability of it...
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--FDA Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or .
Stocks' yearly performance rankings are a field day for contrarians: One year's worst often are the subsequent year's best, and vice versa.
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeut...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The ...
Bristol Myers Squibb has acquired Orum Therapeutics' experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday.
BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb.
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023.